Author

O. Christensen

Observed name: O Christensen

Observed institutions: Bayer (United States), University of Freiburg, University of Cologne, Leiden University Medical Center, University Medical Center Freiburg, Erasmus MC, Universitätsklinik Marien Hospital Herne, Bristol-Myers Squibb (United States), Royal Marsden Hospital, Bayer (Germany), Ruhr University Bochum

OpenAlex ID: A5111696351

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

2012 · D Strumberg, M E Scheulen, et al. · British Journal of Cancer · 249

PDF

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

2006 · D. Strumberg, A. Awada, et al. · European Journal of Cancer · 149

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

2006 · H. Richly, B.F. Henning, et al. · Annals of Oncology · 140

PDF

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib

2006 · K. Mross, S. Steinbild, et al. · European Journal of Cancer · 106

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial

2008 · H. Richly, B. Schultheis, et al. · European Journal of Cancer · 83

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer

2004 · H. Richly, P. Kupsch, et al. · International Journal of Clinical Pharmacology and Therapeutics · 52

Expression and a role of functionally coupled P2Y receptors in human dendritic cells

1999 · Q.H. Liu, H. Bohlen, et al. · FEBS Letters · 47

Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.

2010 · T. Shimizu, A. W. Tolcher, et al. · Journal of Clinical Oncology · 33

Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC).

2010 · M. S. Kies, G. R. Blumenschein, et al. · Journal of Clinical Oncology · 25

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

2008 · D Strumberg, B Schultheis, et al. · British Journal of Cancer · 23

PDF

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors

2011 · M.H.G. Langenberg, P.O. Witteveen, et al. · Annals of Oncology · 22

Phase I study of BAY 43–9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors

2005 · S. Steinbild, F. Baas, et al. · Journal of Clinical Oncology · 15

Phase I study of BAY 73–4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC)

2009 · D. Strumberg, M. E. Scheulen, et al. · Journal of Clinical Oncology · 14

VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function

2006 · N. Steeghs, M. M. Hovens, et al. · Journal of Clinical Oncology · 14

Phase I study of BAY 73–4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors

2007 · S. Hedbom, S. Steinbild, et al. · Journal of Clinical Oncology · 9

Phase I study of BAY 73–4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study

2008 · A. Frost, M. Buechert, et al. · Journal of Clinical Oncology · 8

Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

2015 · S.J. Antonia, J. Bendell, et al. · Annals of Oncology · 7

PDF

VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function

2006 · M.M.C. Hovens, N. Steeghs, et al. · Vascular Pharmacology · 7

3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC)

2015 · E. Calvo, J.A. López-Martin, et al. · European Journal of Cancer · 6

72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors

2006 · H. Gelderblom, J. Verweij, et al. · European Journal of Cancer Supplements · 3

Phase I study of BAY 57–9352, a VEGFR-2 inhibitor, in cycles of 14 days on/7 days off in patients with advanced solid tumors

2006 · D. Strumberg, K. Mross, et al. · Journal of Clinical Oncology · 3

VEGF, sVEGFR-2, bFGF, and IL-8 as biomarkers of the pharmacological activity of BAY 57–9352, an oral VEGFR-2 receptor tyrosine kinase inhibitor, in patients with solid tumors

2006 · M. Zuehlsdorf, O. Christensen, et al. · Journal of Clinical Oncology · 1

B341 BAY 73-4506, A Novel Orally Available Multikinase Inhibitor in MM

2009 · I Breitkreutz, M Raab, et al. · Clinical Lymphoma & Myeloma

Clinical and biomarker responses in a Phase I continuous dose study of telatinib (BAY 57-9352), a VEGFR-2 inhibitor, in patients with colorectal carcinoma

2007 · K. Mross, M. E. Scheulen, et al. · Molecular Cancer Therapeutics

A phase Ib study of telatinib (BAY 57–9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumours

2007 · H. M. Shaw, L. R. Molife, et al. · Journal of Clinical Oncology

Works count: 27

Citation count: 1,016

H-index: 14

I10-index: 14